Orion Biotech Opportunities Corp

Orion Biotech Opportunities Corp. operates as a blank check company. It is a special purpose acquisition company which was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Zuie Chin Huang and Chrystyna Bedrij Stecyk on February 5, 2021 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Orion Biotech Opportunities Corp. operates as a blank check company, which aims to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Zuie Chin Huang and Chrystyna Bedrij Stecyk on February 5, 2021 and is headquartered in New York, NY.

NEW  YORK, July 1, 2021 /PRNewswire/ -- Orion Biotech Opportunities Corp. (Nasdaq: ORIAU) (the "Company" or "us") announced that, commencing July 2, 2021, holders of the units sold in the Company's initial public offering of 20,000,000 units, completed on May 17, 2021, may elect to separately trade the Class A ordinary shares and warrants included in the units. Those units that are not separated at the election of the holder will continue to trade on the Nasdaq Stock Market LLC ("Nasdaq") under the symbol "ORIAU," and the Class A ordinary shares and warrants that are separated will trade on the Nasdaq under the symbols "ORIA" and "ORIAW," respectively.

Orion Biotech Opportunities Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing July 2, 2021

NEW YORK, May 12, 2021 /PRNewswire/ -- Orion Biotech Opportunities Corp. (the "Company") today announced the pricing of its initial public offering ("IPO") of 20,000,000 units at a price of $10.00 per unit. The units will be listed on The Nasdaq Capital Market LLC (the "Nasdaq") and trade under the symbol "ORIAU" beginning May 13, 2021.

Orion Biotech Opportunities Corp. Announces Pricing of $200,000,000 Initial Public Offering

News for Orion Biotech Opportunities Corp Stock (ORIAU)